What is the current valuation of the India meningococcal vaccines market?

As of 2024, the market valuation was 229.5 USD Million. Read More

What is the projected market valuation for the India meningococcal vaccines market by 2035?

The market is expected to reach a valuation of 334.5 USD Million by 2035. Read More

What is the expected CAGR for the India meningococcal vaccines market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 3.48%. Read More

Which companies are the key players in the India meningococcal vaccines market?

Key players include Serum Institute of India, Bharat Biotech, Zydus Cadila, Biological E. Limited, Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer, and Novartis. Read More

What are the main applications of meningococcal vaccines in India?

The main applications include Vaccination Programs, Travel Health, Outbreak Response, Routine Immunization, and Special Population Immunization. Read More

How did the segment for Vaccination Programs perform in 2024?

In 2024, the Vaccination Programs segment was valued between 80.0 and 115.0 USD Million. Read More

What is the valuation range for the Private Healthcare Facilities segment?

The Private Healthcare Facilities segment was valued between 70.0 and 100.0 USD Million in 2024. Read More

Which age group is expected to have the highest market valuation for meningococcal vaccines?

Adults are projected to have the highest market valuation, ranging from 109.5 to 164.5 USD Million. Read More

What types of meningococcal vaccines are available in the Indian market?

Available types include Conjugate Vaccines, Polysaccharide Vaccines, and Recombinant Vaccines. Read More

What is the expected growth trend for the Outbreak Response segment by 2035?

The Outbreak Response segment is projected to grow, with a valuation expected to range from 25.0 to 35.0 USD Million by 2035. Read More

India Meningococcal Vaccines Market

ID: MRFR/Pharma/51390-HCR

200 Pages

Vikita Thakur

Last Updated: February 06, 2026

India Meningococcal Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines, Conjugate Vaccines), By Age Group (Infants, Children, Adolescents, Adults), By Administration Route (Intramuscular, Subcutaneous, Oral) and By Distribution Channel (Hospitals, Clinics, Pharmacies Forecast to 2035

India Meningococcal Vaccines Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Vaccination Programs
  2. 4.1.2 Travel Health
  3. 4.1.3 Outbreak Response
  4. 4.1.4 Routine Immunization
  5. 4.1.5 Special Population Immunization
2. 4.2 Healthcare, BY End Use (USD Million)
  1. 4.2.1 Government Healthcare Facilities
  2. 4.2.2 Private Healthcare Facilities
  3. 4.2.3 Pharmaceutical Distributors
  4. 4.2.4 Non-Governmental Organizations
3. 4.3 Healthcare, BY Age Group (USD Million)
  1. 4.3.1 Infants
  2. 4.3.2 Children
  3. 4.3.3 Adolescents
  4. 4.3.4 Adults
4. 4.4 Healthcare, BY Vaccine Type (USD Million)
  1. 4.4.1 Conjugate Vaccines
  2. 4.4.2 Polysaccharide Vaccines
  3. 4.4.3 Recombinant Vaccines
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Serum Institute of India (IN)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bharat Biotech (IN)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Zydus Cadila (IN)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Biological E. Limited (IN)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi Pasteur (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GlaxoSmithKline (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Novartis (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY APPLICATION
3. 6.3 INDIA MARKET ANALYSIS BY END USE
4. 6.4 INDIA MARKET ANALYSIS BY AGE GROUP
5. 6.5 INDIA MARKET ANALYSIS BY VACCINE TYPE
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY END USE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.2.2 BY END USE, 2026-2035 (USD Million)
  3. 7.2.3 BY AGE GROUP, 2026-2035 (USD Million)
  4. 7.2.4 BY VACCINE TYPE, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

India Healthcare Market Segmentation

Healthcare By Application (USD Million, 2026-2035)

Vaccination Programs
Travel Health
Outbreak Response
Routine Immunization
Special Population Immunization

Healthcare By End Use (USD Million, 2026-2035)

Government Healthcare Facilities
Private Healthcare Facilities
Pharmaceutical Distributors
Non-Governmental Organizations

Healthcare By Age Group (USD Million, 2026-2035)

Infants
Children
Adolescents
Adults

Healthcare By Vaccine Type (USD Million, 2026-2035)

Conjugate Vaccines
Polysaccharide Vaccines
Recombinant Vaccines

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”